Imagine a pharmaceutical prevention, treatment or even cure for Alzheimer’s disease.
It is almost impossible to overstate how monumental a development that would be and how it would answer the prayers of millions.
Though science isn’t there yet, a new study published in The Journal of Neuroscience spearheaded by USC Davis School of Gerontology researchers offers a tantalizing glimpse of potential solutions.
“Our data suggests the possibility of drugs that can prevent and treat Alzheimer’s,” said lead author, professor and lab principal Christian Pike of USC Davis. “It’s just mouse data but extremely encouraging mouse data.”
The team studied the effects of a class of drugs called TSPO ligands on male mice that were genetically engineered to develop Alzheimer’s disease, known as 3xTg-AD mice. Because a key mechanism of TSPO ligands is to increase production of steroid hormones, it was important to ensure that the mice had low levels of testosterone and related hormones before treatment. Younger mice were castrated while, in older mice, the decrease occurred as a normal consequence of aging.
“We looked at the effects of TSPO ligands in young adult mice when pathology was at an early stage and in aged mice when pathology was quite severe,” Pike said. “TSPO ligands reduced measures of pathology and improved behavior at both ages.”
The most surprising finding for Pike and his team was the effect of TSPO ligands in the aged mice. Four treatments — one per week over four weeks — in aged 3xTg-AD mice resulted in significant lowering of Alzheimer’s-related pathology and improvements in memory behavior. This finding suggested the possibility that TSPO ligands can reverse components of Alzheimer’s and thus have the potential to be useful in treatment.
For humans, these findings may indeed be quite significant.
“TSPO ligands are currently used in humans in certain types of neuroimaging. Newer TSPO ligands are at the clinical trials stage of development for treatment of anxiety and other conditions,” Pike said. “There is a strong possibility that TSPO ligands similar to the ones used in our study could be evaluated for therapeutic efficacy in Alzheimer’s patients within the next few years.”
In light of the findings, the team will next focus on understanding how TSPO ligands reduce Alzheimer’s pathology. Building on the established knowledge that TSPO ligands can act protectively by reducing inflammation, shielding nerve cells from injury and increasing the production of neuroactive hormones in the brain, the team will study which of these actions is the most significant in fighting Alzheimer’s so it can develop newer TSPO ligands accordingly.
While Pike and his team acknowledged that the findings represent an exciting possibility, the researchers also stressed that it is by no means a given.
“From the optimistic perspective, our data provide very promising findings with tangible potential benefits for both the prevention and treatment of Alzheimer’s,” Pike said. “On the pessimistic side, research scientists have developed many interventions that cured Alzheimer’s in mice but have failed to show significant benefits in humans. A critical direction we are currently pursuing is successfully translating these findings into humans.”
The Latest Bing News on:
Alzheimer’s
- Alzheimer’s, Cancer To Diabetes: Important Tests To Get Depending On Your Family Historyon April 27, 2024 at 3:49 am
A family history of chronic diseases can put healthy individuals at risk Therefore getting regular tests is crucial for early diagnosis ...
- Challenging Old Theories: Innovative Microscopy Exposes New Alzheimer’s Treatment Pathwayson April 27, 2024 at 3:35 am
Researchers at UC San Diego have utilized advanced imaging techniques to explore the metabolic processes behind Alzheimer's disease, leading to potential new strategies for treatment. Alzheimer's ...
- Commentary: As Alzheimer’s risk grows, caregivers need supporton April 27, 2024 at 2:30 am
According to a new report from the Florida Chapters of the Alzheimer’s Association, an estimated one in eight people are living with Alzheimer’s. More than 840,000 are serving as their unpaid ...
- Alzheimer's All-Star Basketball Classic's founder, Gordon Thomas, inspired by dad's battle with diseaseon April 26, 2024 at 11:50 am
Celeste Taylor, Lester Quinones and Diego Maldonado are just a few of the talented players who have participated in the competitions.
- Neuroscientists Warn of 'Cascading' Alzheimer's Risk From These Two Habitson April 26, 2024 at 10:37 am
The habits produce a "synergistic effect" on our risk of developing Alzheimer's Disease and general cognitive decline.
- AI helps researchers uncover gut-brain interactions in Alzheimer'son April 26, 2024 at 10:00 am
AI technology reveals more information about the gut-brain health link in Alzheimer's, suggesting new pathways for research around treatments.
- Sponsored: Take on Alzheimer's campaign aims to make impact with awareness and supporton April 25, 2024 at 5:28 pm
Public Health Physician Lucia Abascal joined host Jessica Wills to share how the Take on Alzheimer's campaign is helping to spread awareness and erase stigmas surrounding the disease. Watch the clips ...
- For Beaten-Down Maker of Alzheimer’s Drug, Good Enough Will Doon April 25, 2024 at 8:00 am
In-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease drug Skyclarys has Wall Street giving Biogen another chance.
- Florida clinic plans to treat 10,000 Alzheimer’s patients a year. Look at what’s comingon April 25, 2024 at 7:20 am
Roskamp’s planned Bishop-Parker Clinic will enable Roskamp to assess, treat and support more than 10,000 patients a year, Wendy Deming, CEO of the Bishop-Parker Foundation, said Wednesday.
- Biogen cost cuts drive profit beat, as Alzheimer's drug off to slow starton April 24, 2024 at 9:15 am
Biogen reported a quarterly profit that topped Wall Street estimates, helped by cost cutting, as the launch of its new Alzheimer's disease drug remained sluggish. Sales of Alzheimer's drug Leqembi, ...
The Latest Google Headlines on:
Alzheimer’s
[google_news title=”” keyword=”Alzheimer’s” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
TSPO ligands
- Natural ligands of nuclear receptors have conserved volumeson March 12, 2024 at 2:53 am
The sequence homology across the nuclear receptor superfamily indicates that these receptors evolved through divergent evolution 5, but gives no information about the role of ligands in the ...
- TSPO, Hey Smith, Catbite and Kill Lincoln to play Japan showson August 28, 2023 at 6:01 am
Tokyo ska Paradie Orchestra, Hey Smith, Catbite, and Kill Lincoln are playing Japan. The crew has four dates set for late October. You can see the dates below. View this post on Instagram ...
- NKG2 ligands for immune checkpoint modulator researchon August 9, 2021 at 3:42 am
NKG2D acts as an activating receptor. The activation of NKG2D by its ligands — such as MICA, MICB and ULBPs (ULBP1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6) — in human and H60 (a–c), RAE(α–ε ...
The Latest Google Headlines on:
TSPO ligands
[google_news title=”” keyword=”TSPO ligands” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]